Mutual of America Capital Management LLC Purchases 11,881 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Mutual of America Capital Management LLC lifted its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 673.9% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 13,644 shares of the biopharmaceutical company’s stock after purchasing an additional 11,881 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Alnylam Pharmaceuticals were worth $3,684,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Investment Management Corp of Ontario raised its stake in Alnylam Pharmaceuticals by 0.6% during the fourth quarter. Investment Management Corp of Ontario now owns 7,099 shares of the biopharmaceutical company’s stock valued at $1,670,000 after buying an additional 40 shares during the last quarter. Brevan Howard Capital Management LP raised its stake in Alnylam Pharmaceuticals by 3.4% during the fourth quarter. Brevan Howard Capital Management LP now owns 1,333 shares of the biopharmaceutical company’s stock valued at $314,000 after buying an additional 44 shares during the last quarter. Ballentine Partners LLC raised its stake in Alnylam Pharmaceuticals by 3.3% during the first quarter. Ballentine Partners LLC now owns 1,625 shares of the biopharmaceutical company’s stock valued at $439,000 after buying an additional 52 shares during the last quarter. National Bank of Canada FI raised its stake in Alnylam Pharmaceuticals by 9.0% during the fourth quarter. National Bank of Canada FI now owns 668 shares of the biopharmaceutical company’s stock valued at $157,000 after buying an additional 55 shares during the last quarter. Finally, Washington Trust Advisors Inc. raised its stake in Alnylam Pharmaceuticals by 53.5% during the first quarter. Washington Trust Advisors Inc. now owns 175 shares of the biopharmaceutical company’s stock valued at $47,000 after buying an additional 61 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have issued reports on ALNY shares. JPMorgan Chase & Co. lifted their price objective on Alnylam Pharmaceuticals from $348.00 to $475.00 and gave the company an “overweight” rating in a research note on Wednesday. Bank of America lifted their price objective on Alnylam Pharmaceuticals from $336.00 to $359.00 and gave the company a “buy” rating in a research note on Friday, July 11th. UBS Group boosted their price target on Alnylam Pharmaceuticals from $403.00 to $550.00 and gave the stock a “buy” rating in a research note on Friday, August 1st. Wolfe Research upgraded Alnylam Pharmaceuticals from an “underperform” rating to a “peer perform” rating in a research note on Monday, August 4th. Finally, BMO Capital Markets lifted their price objective on Alnylam Pharmaceuticals from $300.00 to $360.00 and gave the stock an “outperform” rating in a report on Tuesday, June 24th. Four analysts have rated the stock with a hold rating, twenty-three have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Alnylam Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $403.92.

Alnylam Pharmaceuticals Stock Performance

NASDAQ:ALNY opened at $438.93 on Friday. The firm has a market capitalization of $57.53 billion, a PE ratio of -177.70 and a beta of 0.25. The company has a debt-to-equity ratio of 4.10, a quick ratio of 2.98 and a current ratio of 2.80. The stock has a 50-day simple moving average of $331.79 and a two-hundred day simple moving average of $284.70. Alnylam Pharmaceuticals, Inc. has a 52-week low of $205.87 and a 52-week high of $439.36.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.86. The firm had revenue of $773,689 billion during the quarter, compared to analyst estimates of $633.54 million. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%. The business’s quarterly revenue was up 17.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.13) earnings per share. Analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other news, CEO Yvonne Greenstreet sold 31,640 shares of the company’s stock in a transaction dated Friday, May 30th. The stock was sold at an average price of $304.39, for a total value of $9,630,899.60. Following the completion of the transaction, the chief executive officer owned 48,948 shares of the company’s stock, valued at $14,899,281.72. This represents a 39.26% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 1.50% of the stock is currently owned by company insiders.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.